Clinical trials: Adenovirus Disease
Adenoviral Conjunctivitis
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
The purpose of this study is to evaluate the safety and efficacy of AL-46383A Ophthalmic Solution for the treatment of adenoviral conjunctivitis.
- Trial name
- NCT00901693
- Testing
- AL-46383A Ophthalmic Solution, AL-46383A Ophthalmic Solution Vehicle
- Volunteers
- 452 people
- Sponsor
- Alcon Research
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Malaria
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults
This is a study designed to assess the safety, tolerability, immunogenicity, and protective efficacy of 2 heterologous prime-boost vaccine regimens in healthy, malaria naïve adults.
- Trial name
- NCT03341754
- Testing
- D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
The purpose of this study is to evaluate the safety and immune response of an adenovirus-based HIV vaccine in HIV-uninfected adults.
- Trial name
- NCT01103687
- Testing
- Ad26.ENVA.01 (rAd26)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Cancer, Epithelial Tumor
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
This study will evaluate the safety, tolerability and preliminary efficacy and also pharmacokinetics, immunogenicity and other pharmacodynamic effects to elucidate the mechanism of action of NG-350A, either alone or in…
- Trial name
- FORTITUDE (NCT03852511)
- Testing
- NG-350A
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Akamis Bio
Liver Cancer, Hepatocellular Carcinoma
Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
HCC patients with tumors >5 cm in diameter, regardless of involvement in the intrahepatic and extrahepatic portal branches participated in the study.
- Trial name
- NCT02202564
- Testing
- LT, ADV-TK, ganciclovir
- Volunteers
- 81 people
- Sponsor
- Huazhong University of Science and Technology
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
The purpose of this study is to assess the safety and immunogenicity of the investigational ChAd3-EBO-Z vaccine administered to approximately 3 000 adults in Africa as a single IM dose Considering the risk of exposure to Ebola…
- Trial name
- NCT02485301
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
- Where
- 5 sites in Cameroon, Mali and 2 more
- Volunteers
- 3,024 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Conjunctivitis
A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis
To engage in a multi-center, prospective, masked clinical trial to investigate a non-invasive, rapid diagnostic test, the RPS Adeno Detector IV's ability to detect the presence of the adenovirus (ADV) antigen in cases of acute…
- Trial name
- NCT00921895
- Testing
- RPS Adeno Detector IV
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Rapid Pathogen Screening
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
CMV Infection, EBV
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or…
- Conditions
- CMV Infection, EBV, Adenovirus
- Trial name
- R3ACT (NCT02779439)
- Testing
- Virus specific CTLs
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Viral Infection
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell…
- Trial name
- TETRAVI (NCT04013802)
- Testing
- HLA-matched VSTs
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Cystic Fibrosis
Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis
OBJECTIVES: I. Assess the safety and feasibility of gene transfer with the third generation adenovirus H5.001CBCFTR in patients with cystic fibrosis.
- Trial name
- NCT00004287
- Testing
- H5.001CBCFTR
- Volunteers
- 14 people
- Sponsor
- National Center for Research Resources (NCRR)
Carcinoma, Transitional Cell, Bladder Neoplasms
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
The main purpose of this research study is to evaluate the safety and dosing of CG0070.
- Trial name
- NCT00109655
- Testing
- Oncolytic adenovirus (serotype 5) - CG0070
- Where
- 10 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Cell Genesys
H5N1 Influenza
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
This is a Phase 1 randomized, single center, dose-escalation study designed to evaluate the safety and immunogenicity of live, replication competent recombinant Adenovirus type 4-H5N1Influenza Vietnam 1194 Hemagglutinin (HA)…
- Trial name
- NCT01443936
- Testing
- Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
- Trial name
- NCT00801697
- Testing
- DNA Vaccine, rAd35, rAd5
- Where
- 10 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase I Study of Vaccination Schedule of Experimental HIV Vaccines
This study will test whether a vaccination schedule of experimental HIV vaccines is safe and whether it causes side effects in healthy adult volunteers.
- Trial name
- NCT00321061
- Testing
- VRC-HIVDNA016-00, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenovirus Infection
Administration of Virus-Specific Cytotoxic T-Lymphocytes
The main purpose of this study is to see if these T-lymphocytes are safe. To make these Ad-specific T lymphocytes the investigators will obtain blood from the stem cell donor and transfer Ad into another type of blood cell…
- Trial name
- LYPTAIST (NCT00590083)
- Testing
- CTL administration
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine
Conjunctivitis, Adenoviral Conjunctivitis
Reducing Adenoviral Patient Infected Days
The primary aim of this pilot study is to generate data needed to design a definitive trial to compare the safety and efficacy of standard care with artificial tears vs.
- Trial name
- RAPID (NCT02472223)
- Testing
- Betadine 5%, Artificial Tears
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Metastatic Melanoma
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma
This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in…
- Trial name
- TUNINTIL (NCT04217473)
- Testing
- TILT-123
- Where
- 2 sites in Denmark, France
- Volunteers
- 17 people
- Sponsor
- TILT Biotherapeutics Ltd.
Healthy Adult Immune Responses to Vaccine
Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults
Background: Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02231866
- Testing
- VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP
- Where
- 3 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)